ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels
Patients with a transient ischemic attack or minor stroke had a sustained elevated risk of CV events up to 5 years after the first event, and approximately half of these events occurred after the first year.
ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.
ACC 2018 When clinical characteristics were combined with genetic information to inform the choice of P2Y12 inhibitor after ACS, patients experienced 42% fewer MI, stroke, CV death or major bleeding.
ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
In a single-center observational study, less than 50% of acute coronary syndrome patients were on recommended therapies at discharge, which was associated with an increase in 1-year mortality.
Meta-analysis shows that in patients with recent ACS, addition of a NOAC to dual antiplatelet therapy resulted in a modest reduction of major adverse CV events but led to higher bleeding risk.
Two documents summarize the main messages of the ESC 2017 STEMI management guidelines, namely changes with respect to the 2012 version and ‘ten commandments’ to follow.
AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.
Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.
ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..